NCT07392359Not yet recruitingNot Applicable
Prospective, Multicentre, Randomised Controlled, Non-Inferiority Clinical Trial Evaluating the Safety and Efficacy of the TAVR Assist System and Its Disposable Kit for Use as an Adjunct to TAVR
Zhicheng Medical Technology (Jiaxing) Co, Ltd0 sites158 target enrollmentStarted: February 15, 2026Last updated:
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 158
- Primary Endpoint
- Technical Success at exit from OR, hybrid room or cath lab post-index procedure
Study Overview
Brief Summary
Use of the Transcatheter Aortic Valve Replacement Surgical Assist System and its Disposable Kit in Patients With Severe Aortic Stenosis to Evaluate the Safety and Efficacy of the Transcatheter Aortic Valve Replacement Surgical Assist System and its Disposable Kit for Use as an Adjunct to Transcatheter Aortic Valve Replacement
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 65 Years to 100 Years (Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Age ≥65 years old, gender is not limited;
- •Patients assessed by a cardiac multidisciplinary team (MDT) expert panel as having severe aortic stenosis and suitable for transcatheter aortic valve replacement;
- •*Severe aortic stenosis was defined as echocardiographically demonstrated transaortic valve flow velocity ≥4.0 m/s, or transaortic valve pressure differential ≥40 mmHg (1 mmHg=0.133 kPa), or aortic orifice area <1.0 cm2, or effective aortic orifice area index <0.6 cm2/m2; for low-pressure-differential-low-flow rate by dopa-phenobutylamine loading test, Doppler ultrasound evaluation or other imaging means of assessment for those judged to have severe aortic stenosis.
- •Have a core laboratory assessment that the patient is anatomically suitable for transcatheter aortic valve replacement;
- •Patients who understand the purpose of the trial, voluntarily participate in the trial, sign an informed consent form, and are willing to cooperate in the follow-up.
Exclusion Criteria
- •Patients whose access or aortic root anatomical pattern is unsuitable for TAVR treatment;
- •Poor peripheral arterial conditions that preclude transfemoral TAVR;
- •Aortic annulus horizontal pinch angle ≥65° as measured by preoperative MDCT;
- •Patients at high risk of coronary obstruction requiring intraoperative coronary protection measures;
- •Patients requiring intraoperative delivery with a grapple assist system;
- •Previous implantation of a prosthetic aortic valve (bioprosthetic or mechanical);
- •Active stage of infective endocarditis or other active infection;
- •Combined mitral, tricuspid or severe macrovascular lesions requiring surgical or interventional intervention;
- •Echocardiography suggestive of left ventricular thrombus, intracardiac mass or redundant organisms;
- •Diagnosis of hypertrophic cardiomyopathy, restrictive cardiomyopathy, infiltrative cardiomyopathy (e.g. amyloidosis, haemochromatosis, nodular disease, etc.), constrictive pericarditis;
- •Severe obstruction of the left ventricular outflow tract without corrective measures;
- •Severe pulmonary hypertension (pulmonary artery systolic pressure >70 mmHg measured by ultrasound);
- •Severe right heart dysfunction as suggested by a combined clinical and ultrasound assessment;
- •Severe left heart systolic insufficiency (left ventricular ejection fraction <30%);
- •Cardiogenic shock or haemodynamic instability requiring ventricular assist device therapy within 30 days prior to enrolment;
- •End-stage heart failure (ACC/AHA Stage D), or post cardiac transplantation, or awaiting cardiac transplantation;
- •Acute myocardial infarction within 30 days prior to enrolment;
- •Has had a stroke within 3 months prior to enrolment;
- •Stenosis of the common or internal carotid artery or vertebral artery (>70% stenosis) requiring treatment as recommended by the relevant disciplinary consultation;
- •Severe cardiac and aortic disease requiring concomitant treatment, including ascending aortic aneurysm (maximum diameter ≥ 50 mm);
- •Severe renal insufficiency (estimated glomerular filtration rate <30mL/min/1.73m2);
- •Active peptic ulcer or history of upper gastrointestinal bleeding within 3 months prior to enrolment;
- •Severe coagulopathy; Patients with known intolerance to anticoagulant, antiplatelet drugs or anaesthetic drugs; Patients who have participated in other drug or medical device clinical trials prior to enrolment that have not met the primary endpoint; Patients who, in the opinion of the investigator, are not suitable for participation in this clinical trial
Arms & Interventions
TAVR By Manual
Placebo Comparator
Intervention: TAVR by manual (Other)
TAVR with TAVR Assistance System
Experimental
Intervention: TAVR Assistance System (Device)
Outcomes
Primary Outcomes
Technical Success at exit from OR, hybrid room or cath lab post-index procedure
Time Frame: Immediate after procedure
Absence of procedural mortality; and Successful access, delivery, and retrieval of transcatheter delivery system; and Deployment and correct positioning of a single intended THV; and Freedom from re-intervention related to the device or access procedure
Secondary Outcomes
- Device Success(30 days)
- Cardiac function changement(Baseline，30 days)
- Prosthetic aortic valve function(1、immediately after the procedure; 2、3 days; 3、30 days)
- Duration of aortic valve replacement(During the procedure)
- Total exposure of the operator to radiation(During the procedure)
- Number of surgical staff(During the procedure)
- Evaluation of Device Performance with questionnaires(immediately after the procedure)
Investigators
Similar Trials
Recruiting
Not Applicable
STAR Trial (Siegel Transcatheter Aortic Valve Replacement in Patients With Symptomatic Severe Aortic Stenosis)Aortic StenosisSymptomatic Severe Native Aortic StenosisNCT07278310MiRus1,025
Not yet recruiting
Phase 4
Echo-Guided vs Fluoroscopy-Guided Transcatheter Aortic Valve Replacement in Patients With Aortic Stenosis（ECHO-TAVR）Aortic StenosisNCT07317804China National Center for Cardiovascular Diseases212
Recruiting
Not Applicable
Comparative Research of Y-Incision vs. Standard Techniques for Aortic Root EnLargementNCT07368322willner nadav MD90
Active, not recruiting
Not Applicable
Electrophysiological Outcomes After Transcatheter Aortic Valve ReplacementArrhythmiaNCT07390513Chinese Academy of Medical Sciences, Fuwai Hospital1,000
Unknown
Not Applicable
Transcatheter Aortic Valve Replacement System Pivotal TrialAortic Valve StenosisNCT02163850Direct Flow Medical, Inc.878